<div id="readability-page-1"><p>Ionis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 157 million compared to USD 134 million a year ago. Net loss was USD 129 million compared to USD 140 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 0.95 a year ago. Diluted loss per share from continuing operations was USD 0.8 compared to USD 0.95 a year ago.<br/> For the nine months, revenue was USD 740 million compared to USD 479 million a year ago. Net loss was USD 152 million compared to USD 350 million a year ago. Basic loss per share from continuing operations was USD 0.95 compared to USD 2.38 a year ago. Diluted loss per share from continuing operations was USD 0.95 compared to USD 2.38 a year ago.</p></div>

Ionis制药

<p>Ionis 制药公司报告了 2025 年第三季度及前九个月的财务业绩。第三季度收入同比增长至 1.57 亿美元，较去年同期的 1.34 亿美元有所增加，净亏损为 1.29 亿美元，较去年同期的 1.4 亿美元有所改善。在前九个月，收入从 4.79 亿美元上升至 7.4 亿美元，净亏损为 1.52 亿美元，较 3.5 亿美元有所减少。来自持续经营的基本和稀释每股亏损分别改善至 0.8 美元和 0.95 美元，而去年同期为 0.95 美元和 2.38 美元</p>

Ionis 制药公司公布了截至2025年9月30日的第三季度和九个月的财务业绩